334 related articles for article (PubMed ID: 36333618)
1. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
Morita A; Choon SE; Bachelez H; Anadkat MJ; Marrakchi S; Zheng M; Tsai TF; Turki H; Hua H; Rajeswari S; Thoma C; Burden AD
Dermatol Ther (Heidelb); 2023 Jan; 13(1):347-359. PubMed ID: 36333618
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.
Morita A; Tsai TF; Yee EYW; Okubo Y; Imafuku S; Zheng M; Li L; Quaresma M; Thoma C; Choon SE
J Dermatol; 2023 Feb; 50(2):183-194. PubMed ID: 36282833
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Morita A; Strober B; Burden AD; Choon SE; Anadkat MJ; Marrakchi S; Tsai TF; Gordon KB; Thaçi D; Zheng M; Hu N; Haeufel T; Thoma C; Lebwohl MG
Lancet; 2023 Oct; 402(10412):1541-1551. PubMed ID: 37738999
[TBL] [Abstract][Full Text] [Related]
4. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare.
Choon SE; Lebwohl MG; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Rajeswari S; Deng H; Tetzlaff K; Thoma C; Bachelez H
BMJ Open; 2021 Mar; 11(3):e043666. PubMed ID: 33785490
[TBL] [Abstract][Full Text] [Related]
5. Trial of Spesolimab for Generalized Pustular Psoriasis.
Bachelez H; Choon SE; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Anadkat MJ; Rajeswari S; Hua H; Vulcu SD; Hall D; Tetzlaff K; Thoma C; Lebwohl MG;
N Engl J Med; 2021 Dec; 385(26):2431-2440. PubMed ID: 34936739
[TBL] [Abstract][Full Text] [Related]
6. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
Elewski BE; Lebwohl MG; Anadkat MJ; Barker J; Ghoreschi K; Imafuku S; Mrowietz U; Li L; Quaresma M; Thoma C; Bachelez H
J Am Acad Dermatol; 2023 Jul; 89(1):36-44. PubMed ID: 36870370
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial.
Tsai TF; Zheng M; Ding Y; Song Z; Liu Q; Chen Y; Hu H; Xu J
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3097-3110. PubMed ID: 37840119
[TBL] [Abstract][Full Text] [Related]
8. Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study.
Navarini AA; Prinz JC; Morita A; Tsai TF; Viguier MA; Li L; Thoma C; Sivalingam M; Lebwohl MG
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):730-736. PubMed ID: 36527385
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.
Burden AD; Okubo Y; Zheng M; Thaçi D; van de Kerkhof P; Hu N; Quaresma M; Thoma C; Choon SE
Exp Dermatol; 2023 Aug; 32(8):1279-1283. PubMed ID: 37140190
[TBL] [Abstract][Full Text] [Related]
10. Spesolimab for the Treatment of Generalized Pustular Psoriasis.
Bernardo D; Thaçi D; Torres T
Drugs; 2024 Jan; 84(1):45-58. PubMed ID: 38114719
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Clinical Assessment, Guidelines, and Options for the Treatment of Generalized Pustular Psoriasis [Podcast].
Song EJ; Liu C
Clin Cosmet Investig Dermatol; 2023; 16():2911-2917. PubMed ID: 37915421
[TBL] [Abstract][Full Text] [Related]
12. The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab.
Hawkes JE; Visvanathan S; Krueger JG
Front Immunol; 2023; 14():1292941. PubMed ID: 38077370
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report.
Wen P; Liu C; Wang T; Jiang X; Wang P; Wang S
Front Immunol; 2024; 15():1338285. PubMed ID: 38464535
[TBL] [Abstract][Full Text] [Related]
14. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares.
Choon SE; Lebwohl MG; Turki H; Zheng M; Burden AD; Li L; Quaresma M; Thoma C; Bachelez H
Dermatology; 2023; 239(3):345-354. PubMed ID: 36796336
[TBL] [Abstract][Full Text] [Related]
16. Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis.
Shao S; Wang G
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2627-2635. PubMed ID: 36208408
[TBL] [Abstract][Full Text] [Related]
17. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis.
Burden AD
Expert Rev Clin Immunol; 2023 May; 19(5):473-481. PubMed ID: 36960829
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation.
Potestio L; Camela E; Cacciapuoti S; Martora F; Guerriero L; Fornaro L; Ruggiero A; Megna M
Expert Opin Drug Saf; 2023; 22(11):1003-1010. PubMed ID: 37768729
[TBL] [Abstract][Full Text] [Related]
19. Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
Megna M; Camela E; Ruggiero A; Battista T; Martora F; Cacciapuoti S; Potestio L
Clin Cosmet Investig Dermatol; 2023; 16():1677-1690. PubMed ID: 37404368
[TBL] [Abstract][Full Text] [Related]
20. Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.
Bukhari T; Markovina M; Abduelmula A; Rankin BD; Vender R; Yeung J; Devani AR; Prajapati VH
Skin Therapy Lett; 2024 Jan; 29(1):1-4. PubMed ID: 38271532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
